The Cooper Companies, Inc. (NASDAQ: COO) Stock Competitors & Peer Comparison
See COO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for COO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COO | $63.57 | -0.56% | 12.1B | 13.94 | $4.56 | N/A |
| ISRG | $450.04 | -2.28% | 156B | 46.78 | $9.62 | N/A |
| BDX | $212.61 | -1.23% | 57.9B | 16.35 | $13.00 | +1.86% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +1.86% |
| MDLN | $40.91 | +0.49% | 35.9B | 29.98 | $1.36 | N/A |
| RMD | $234.11 | -0.69% | 32.9B | 20.31 | $11.53 | +1.06% |
| WST | $412.55 | -0.07% | 28.7B | 44.86 | $9.20 | +0.22% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.08 | -0.39% | 15.3B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +1.86% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
COO vs ISRG Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, ISRG has a market cap of 156B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while ISRG trades at $450.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas ISRG's P/E ratio is 46.78. In terms of profitability, COO's ROE is +0.07%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, COO is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for COO.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDX)
COO vs BDX Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, BDX has a market cap of 57.9B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while BDX trades at $212.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas BDX's P/E ratio is 16.35. In terms of profitability, COO's ROE is +0.07%, compared to BDX's ROE of +0.04%. Regarding short-term risk, COO is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for COO.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
COO vs BDXA Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas BDXA's P/E ratio is 45.70. In terms of profitability, COO's ROE is +0.07%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, COO is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for COO.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
COO vs MDLN Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, MDLN has a market cap of 35.9B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while MDLN trades at $40.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas MDLN's P/E ratio is 29.98. In terms of profitability, COO's ROE is +0.07%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, COO is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for COO.Check MDLN's competition here
ResMed Inc. (NYSE: RMD)
COO vs RMD Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, RMD has a market cap of 32.9B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while RMD trades at $234.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas RMD's P/E ratio is 20.31. In terms of profitability, COO's ROE is +0.07%, compared to RMD's ROE of +0.25%. Regarding short-term risk, COO is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for COO.Check RMD's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
COO vs WST Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, WST has a market cap of 28.7B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while WST trades at $412.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas WST's P/E ratio is 44.86. In terms of profitability, COO's ROE is +0.07%, compared to WST's ROE of +0.21%. Regarding short-term risk, COO is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for COO.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
COO vs HOLX Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas HOLX's P/E ratio is 31.54. In terms of profitability, COO's ROE is +0.07%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, COO is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for COO.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
COO vs SOLV Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, SOLV has a market cap of 15.3B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while SOLV trades at $90.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas SOLV's P/E ratio is 12.69. In terms of profitability, COO's ROE is +0.07%, compared to SOLV's ROE of +0.03%. Regarding short-term risk, COO is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for COO.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
COO vs BDXB Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas BDXB's P/E ratio is 7.60. In terms of profitability, COO's ROE is +0.07%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, COO is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for COO.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
COO vs BAX Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, BAX has a market cap of 13.7B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while BAX trades at $26.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas BAX's P/E ratio is 12.70. In terms of profitability, COO's ROE is +0.07%, compared to BAX's ROE of -0.12%. Regarding short-term risk, COO is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for COO.Check BAX's competition here
Repligen Corporation (NASDAQ: RGEN)
COO vs RGEN Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, RGEN has a market cap of 11.1B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while RGEN trades at $173.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas RGEN's P/E ratio is 96.66. In terms of profitability, COO's ROE is +0.07%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, COO is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for COO.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
COO vs AVTR Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, AVTR has a market cap of 10.6B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while AVTR trades at $15.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas AVTR's P/E ratio is 18.32. In terms of profitability, COO's ROE is +0.07%, compared to AVTR's ROE of +0.06%. Regarding short-term risk, COO is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for COO.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
COO vs ATR Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, ATR has a market cap of 9.1B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while ATR trades at $144.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas ATR's P/E ratio is 25.19. In terms of profitability, COO's ROE is +0.07%, compared to ATR's ROE of +0.10%. Regarding short-term risk, COO is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for COO.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
COO vs BLCO Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, BLCO has a market cap of 7.6B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while BLCO trades at $21.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas BLCO's P/E ratio is 32.88. In terms of profitability, COO's ROE is +0.07%, compared to BLCO's ROE of -0.02%. Regarding short-term risk, COO is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for COO.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
COO vs TFX Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, TFX has a market cap of 6.6B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while TFX trades at $155.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas TFX's P/E ratio is 17.76. In terms of profitability, COO's ROE is +0.07%, compared to TFX's ROE of +0.10%. Regarding short-term risk, COO is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for COO.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
COO vs MMSI Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, MMSI has a market cap of 5.3B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while MMSI trades at $87.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas MMSI's P/E ratio is 22.46. In terms of profitability, COO's ROE is +0.07%, compared to MMSI's ROE of +0.10%. Regarding short-term risk, COO is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for COO.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
COO vs ICUI Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, ICUI has a market cap of 4.6B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while ICUI trades at $182.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas ICUI's P/E ratio is 22.74. In terms of profitability, COO's ROE is +0.07%, compared to ICUI's ROE of +0.03%. Regarding short-term risk, COO is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for COO.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
COO vs NVST Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, NVST has a market cap of 4.1B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while NVST trades at $25.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas NVST's P/E ratio is 17.56. In terms of profitability, COO's ROE is +0.07%, compared to NVST's ROE of +0.21%. Regarding short-term risk, COO is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for COO.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
COO vs PLSE Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, PLSE has a market cap of 4B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while PLSE trades at $55.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas PLSE's P/E ratio is -46.71. In terms of profitability, COO's ROE is +0.07%, compared to PLSE's ROE of -0.78%. Regarding short-term risk, COO is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for COO.Check PLSE's competition here
Stevanato Group S.p.A. (NYSE: STVN)
COO vs STVN Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, STVN has a market cap of 3.7B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while STVN trades at $13.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas STVN's P/E ratio is 20.47. In terms of profitability, COO's ROE is +0.07%, compared to STVN's ROE of +0.09%. Regarding short-term risk, COO is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for COO.Check STVN's competition here
AtriCure, Inc. (NASDAQ: ATRC)
COO vs ATRC Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while ATRC trades at $56.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas ATRC's P/E ratio is 1747.20. In terms of profitability, COO's ROE is +0.07%, compared to ATRC's ROE of +0.03%. Regarding short-term risk, COO is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for COO.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
COO vs XRAY Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, XRAY has a market cap of 1.9B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while XRAY trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas XRAY's P/E ratio is 6.78. In terms of profitability, COO's ROE is +0.07%, compared to XRAY's ROE of -0.09%. Regarding short-term risk, COO is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for COO.Check XRAY's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
COO vs BLFS Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while BLFS trades at $38.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas BLFS's P/E ratio is 37.49. In terms of profitability, COO's ROE is +0.07%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, COO is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for COO.Check BLFS's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
COO vs LMAT Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while LMAT trades at $79.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas LMAT's P/E ratio is 29.05. In terms of profitability, COO's ROE is +0.07%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, COO is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for COO.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
COO vs AZTA Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, AZTA has a market cap of 1.8B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while AZTA trades at $40.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas AZTA's P/E ratio is 96.38. In terms of profitability, COO's ROE is +0.07%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, COO is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for COO.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
COO vs KMTS Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, KMTS has a market cap of 1.8B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while KMTS trades at $29.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas KMTS's P/E ratio is -11.15. In terms of profitability, COO's ROE is +0.07%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, COO is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for COO.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
COO vs STAA Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while STAA trades at $23.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas STAA's P/E ratio is 41.88. In terms of profitability, COO's ROE is +0.07%, compared to STAA's ROE of +0.00%. Regarding short-term risk, COO is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for COO.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
COO vs ATRI Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas ATRI's P/E ratio is 64.50. In terms of profitability, COO's ROE is +0.07%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, COO is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for COO.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
COO vs ANGO Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, ANGO has a market cap of 508.4M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while ANGO trades at $12.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas ANGO's P/E ratio is -31.00. In terms of profitability, COO's ROE is +0.07%, compared to ANGO's ROE of -0.19%. Regarding short-term risk, COO is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for COO.Check ANGO's competition here
MiniMed Group, Inc. (NASDAQ: MMEDV)
COO vs MMEDV Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, MMEDV has a market cap of 495.6M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while MMEDV trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas MMEDV's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.07%, compared to MMEDV's ROE of N/A. Regarding short-term risk, COO is less volatile compared to MMEDV. This indicates lower risk in terms of short-term price fluctuations for COO.Check MMEDV's competition here
Embecta Corp. (NASDAQ: EMBC)
COO vs EMBC Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, EMBC has a market cap of 364.3M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while EMBC trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas EMBC's P/E ratio is 2.47. In terms of profitability, COO's ROE is +0.07%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, COO is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for COO.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
COO vs SMTI Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, SMTI has a market cap of 290.9M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while SMTI trades at $31.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas SMTI's P/E ratio is -527.67. In terms of profitability, COO's ROE is +0.07%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, COO is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for COO.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
COO vs OSUR Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, OSUR has a market cap of 229.7M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while OSUR trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas OSUR's P/E ratio is -4.83. In terms of profitability, COO's ROE is +0.07%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, COO is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for COO.Check OSUR's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
COO vs PDEX Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, PDEX has a market cap of 223.6M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while PDEX trades at $69.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas PDEX's P/E ratio is 19.14. In terms of profitability, COO's ROE is +0.07%, compared to PDEX's ROE of +0.26%. Regarding short-term risk, COO is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for COO.Check PDEX's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
COO vs UTMD Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, UTMD has a market cap of 207.6M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while UTMD trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas UTMD's P/E ratio is 21.56. In terms of profitability, COO's ROE is +0.07%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, COO is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for COO.Check UTMD's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
COO vs NNNN Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, NNNN has a market cap of 166.8M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while NNNN trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas NNNN's P/E ratio is 25.33. In terms of profitability, COO's ROE is +0.07%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, COO is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for COO.Check NNNN's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
COO vs KRMD Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while KRMD trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas KRMD's P/E ratio is -79.00. In terms of profitability, COO's ROE is +0.07%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, COO is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for COO.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
COO vs STXS Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, STXS has a market cap of 105.2M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while STXS trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas STXS's P/E ratio is -6.18. In terms of profitability, COO's ROE is +0.07%, compared to STXS's ROE of -1.33%. Regarding short-term risk, COO is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for COO.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
COO vs AKYA Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas AKYA's P/E ratio is -1.34. In terms of profitability, COO's ROE is +0.07%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, COO is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for COO.Check AKYA's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
COO vs POCI Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, POCI has a market cap of 55.7M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while POCI trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas POCI's P/E ratio is -11.04. In terms of profitability, COO's ROE is +0.07%, compared to POCI's ROE of -0.24%. Regarding short-term risk, COO is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for COO.Check POCI's competition here
SkyAI, Inc. (NASDAQ: STSS)
COO vs STSS Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas STSS's P/E ratio is -0.02. In terms of profitability, COO's ROE is +0.07%, compared to STSS's ROE of -0.99%. Regarding short-term risk, COO is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for COO.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
COO vs OMIC Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas OMIC's P/E ratio is -0.58. In terms of profitability, COO's ROE is +0.07%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, COO is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for COO.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
COO vs IGAP Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas IGAP's P/E ratio is -10.52. In terms of profitability, COO's ROE is +0.07%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, COO is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for COO.Check IGAP's competition here
Daxor Corporation (NASDAQ: DXR)
COO vs DXR Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, DXR has a market cap of 49.3M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while DXR trades at $8.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas DXR's P/E ratio is 6.87. In terms of profitability, COO's ROE is +0.07%, compared to DXR's ROE of +0.13%. Regarding short-term risk, COO is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for COO.Check DXR's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
COO vs HBIO Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, HBIO has a market cap of 42.2M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while HBIO trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas HBIO's P/E ratio is -25.72. In terms of profitability, COO's ROE is +0.07%, compared to HBIO's ROE of -1.30%. Regarding short-term risk, COO is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for COO.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
COO vs NEPH Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, NEPH has a market cap of 34.2M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while NEPH trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas NEPH's P/E ratio is 52.50. In terms of profitability, COO's ROE is +0.07%, compared to NEPH's ROE of +0.17%. Regarding short-term risk, COO is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for COO.Check NEPH's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
COO vs ZJYL Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, ZJYL has a market cap of 33M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while ZJYL trades at $4.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas ZJYL's P/E ratio is 28.80. In terms of profitability, COO's ROE is +0.07%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, COO is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for COO.Check ZJYL's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
COO vs SDC Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas SDC's P/E ratio is -0.03. In terms of profitability, COO's ROE is +0.07%, compared to SDC's ROE of -1.96%. Regarding short-term risk, COO is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for COO.Check SDC's competition here
Milestone Scientific Inc. (AMEX: MLSS)
COO vs MLSS Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, MLSS has a market cap of 27.8M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while MLSS trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas MLSS's P/E ratio is -6.14. In terms of profitability, COO's ROE is +0.07%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, COO is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for COO.Check MLSS's competition here
Invacare Corporation (NYSE: IVC)
COO vs IVC Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas IVC's P/E ratio is -0.79. In terms of profitability, COO's ROE is +0.07%, compared to IVC's ROE of -0.46%. Regarding short-term risk, COO is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for COO.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
COO vs RVP Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, RVP has a market cap of 16.6M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while RVP trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas RVP's P/E ratio is -4.62. In terms of profitability, COO's ROE is +0.07%, compared to RVP's ROE of -0.05%. Regarding short-term risk, COO is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for COO.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
COO vs BNGO Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, BNGO has a market cap of 14.5M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while BNGO trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas BNGO's P/E ratio is -0.41. In terms of profitability, COO's ROE is +0.07%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, COO is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for COO.Check BNGO's competition here
Femasys Inc. (NASDAQ: FEMY)
COO vs FEMY Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, FEMY has a market cap of 12M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while FEMY trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas FEMY's P/E ratio is -0.32. In terms of profitability, COO's ROE is +0.07%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, COO is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for COO.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
COO vs RGNT Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, RGNT has a market cap of 9.2M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while RGNT trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas RGNT's P/E ratio is -0.53. In terms of profitability, COO's ROE is +0.07%, compared to RGNT's ROE of N/A. Regarding short-term risk, COO is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for COO.Check RGNT's competition here
Lucyd, Inc (NASDAQ: LUCY)
COO vs LUCY Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, LUCY has a market cap of 7.5M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while LUCY trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas LUCY's P/E ratio is -0.67. In terms of profitability, COO's ROE is +0.07%, compared to LUCY's ROE of -1.03%. Regarding short-term risk, COO is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for COO.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
COO vs NSTG Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas NSTG's P/E ratio is -0.03. In terms of profitability, COO's ROE is +0.07%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, COO is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for COO.Check NSTG's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
COO vs CUPR Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, CUPR has a market cap of 4.7M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while CUPR trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas CUPR's P/E ratio is -1.27. In terms of profitability, COO's ROE is +0.07%, compared to CUPR's ROE of -0.85%. Regarding short-term risk, COO is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for COO.Check CUPR's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
COO vs POAI Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas POAI's P/E ratio is -0.38. In terms of profitability, COO's ROE is +0.07%, compared to POAI's ROE of -21.19%. Regarding short-term risk, COO is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for COO.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
COO vs MHUA Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas MHUA's P/E ratio is 0.25. In terms of profitability, COO's ROE is +0.07%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, COO is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for COO.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
COO vs GMVD Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas GMVD's P/E ratio is -0.01. In terms of profitability, COO's ROE is +0.07%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, COO is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for COO.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
COO vs GMVDW Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas GMVDW's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.07%, compared to GMVDW's ROE of +3.68%. Regarding short-term risk, COO is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for COO.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
COO vs NXGL Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, NXGL has a market cap of 1.7M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while NXGL trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas NXGL's P/E ratio is -5.06. In terms of profitability, COO's ROE is +0.07%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, COO is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for COO.Check NXGL's competition here
Avinger, Inc. (NASDAQ: AVGR)
COO vs AVGR Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas AVGR's P/E ratio is -0.05. In terms of profitability, COO's ROE is +0.07%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, COO is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for COO.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
COO vs NXGLW Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, NXGLW has a market cap of 395.5K. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, COO's ROE is +0.07%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, COO is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for COO.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
COO vs LUCYW Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas LUCYW's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.07%, compared to LUCYW's ROE of -1.03%. Regarding short-term risk, COO is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for COO.Check LUCYW's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
COO vs ATRS Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas ATRS's P/E ratio is 14.95. In terms of profitability, COO's ROE is +0.07%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, COO is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for COO.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
COO vs IVTY Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas IVTY's P/E ratio is -3.80. In terms of profitability, COO's ROE is +0.07%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, COO is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for COO.Check IVTY's competition here
Analogic Corporation (NASDAQ: ALOG)
COO vs ALOG Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas ALOG's P/E ratio is 40.93. In terms of profitability, COO's ROE is +0.07%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, COO is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for COO.Check ALOG's competition here
Apria, Inc. (NASDAQ: APR)
COO vs APR Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, APR has a market cap of 0. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas APR's P/E ratio is 22.59. In terms of profitability, COO's ROE is +0.07%, compared to APR's ROE of +9.81%. Regarding short-term risk, COO is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for COO.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
COO vs HRC Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, HRC has a market cap of 0. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas HRC's P/E ratio is 41.92. In terms of profitability, COO's ROE is +0.07%, compared to HRC's ROE of +0.14%. Regarding short-term risk, COO is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for COO.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
COO vs IIN Comparison November 2026
The Cooper Companies, Inc. (NASDAQ: COO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 12.1B. In comparison, IIN has a market cap of 0. Regarding current trading prices, COO is priced at $63.57 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 13.94, whereas IIN's P/E ratio is 226.45. In terms of profitability, COO's ROE is +0.07%, compared to IIN's ROE of -0.00%. Regarding short-term risk, COO is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for COO.Check IIN's competition here